Custo-efetividade da inclusão dos respondedores virológicos lentos no tratamento da hepatite C na presença da coinfecção com o HIV

Rodrigues, Marcus Paulo da Silva; Vianna, Cid Manso de Mello; Mosegui, Gabriela Bittencourt Gonzalez; Silva, Frances Valéria Costa e; Peregrino, Antonio Augusto de Freitas; Jardim, Fernando Nagib.
Cad. saúde pública ; 29(supl.1): s146-s158, Nov. 2013. ilus, graf, tab
Artigo em Português | LILACS | ID: lil-690747

Documentos relacionados

  1. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
  2. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
  3. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.
  4. [Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis].
  5. [Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
  6. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
  7. Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus.
  8. Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.
  9. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
  10. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population.